LICENSE AGREEMENT

“Accelr8 Intellectual Property” means the Accelr8 Know-How and Accelr8 Patents.

“Accelr8 Know-How” means all tangible and intangible (a) techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, processes (including manufacturing and quality control processes), knowledge, know-how, skill, experience, test data and results (including pharmacological, toxicological and clinical test data and results), analytical and quality control data, results or descriptions, software and algorithms, and (b) compounds, compositions of matter, complexes and physical, biological or chemical material, which exist as of the Effective Date and are related to Accelr8’s proprietary surface chemistry and coating technology.

“Accelr8 Patents” means (a) those Patents and Patent Applications listed in Appendix A, and (b) any Patents owned or licensed (with a right of sublicense) by Accelr8 that cover the Process Improvements.

“Affiliate” means every corporation, or entity, which, directly or indirectly, or through one or more intermediaries, controls, is controlled by, or is under common control with a Party, as well as every officer, director, agent and representative of any such corporation or entity. For the purposes of the foregoing definition, the word “control” (including, with correlative meaning, the terms “controlled by” or “under common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.

“Calendar Quarter” means any period of three (3) consecutive months ending on March 31, June 30, September 30 and December 31.

“Coatings” means surface films used to immobilize molecules and other materials for the purpose of analysis.

“Confidential Information” has the meaning set forth in §7.01.

“Effective Date” means the date specified in the first paragraph of this Agreement.

“Improvements” means inventions, discoveries, works of authorship, trade secrets, know-how or developments, whether or not patentable, that are made, conceived, reduced to practice or otherwise generated during the Term, which are improvements, modifications or other developments to the Licensed Product (including, without limitation, the manufacturing processes for such products and/or the OptiChem^® coating technology).

“Inventions” means all Improvements, inventions, discoveries, processes, works of authorship, trade secrets and other know-how, developments or the like, whether or not patentable, that are made, conceived, reduced to practice or otherwise generated solely by a Party or jointly by the Parties as a result of this Agreement (including, without limitation, Inventions related to the Licensed Product or its manufacture).

“License Fee” has the meaning set forth in §5.01.

“Licensed Product” means the Accelr8 product described in Appendix B and applied to any Nanosphere Product.

“Nanosphere Product” means a manufactured discrete physical article that completes the production process, for any use as a finished functional article that is not discarded as in-process waste, for whatever manner of use after said production, including but not limited to any manner of sale, product development, product trials, or free goods for evaluation by a customer, distributor, or commercial collaborator.

“Patents” means:

(a) United States and foreign patents and/or patent applications and/or provisional patent applications;

(b) United States and foreign patents issued from the applications described in (a) above and from divisionals and continuations and continuations-in-part of these applications;

(c) U.S. and foreign continuations and continuation-in-part applications, and the resulting patents of any of the U.S. and foreign applications described in (a) or (b) above or this paragraph (c); and

(d) any reissues of United States and foreign patents described in (a), (b) or (c) above.

“Process Improvements” means any Improvements to the processes for the manufacture of the Licensed Product.

“Term” means the term of this Agreement, as determined in accordance with Article 10.

“Third Party” means any entity or person other than Accelr8 or Nanosphere.

Accelr8 hereby grants, and Nanosphere accepts, during the Term and subject to the terms and conditions of this Agreement, a worldwide, non-transferable (except as provided in §12.01), fee-bearing non-exclusive license under the Accelr8 Intellectual Property to make, have made, use, sell, offer to sell, import, have imported, export, and distribute the Licensed Product exclusively as applied to Nanosphere Products, including products produced by Nanosphere for any Third Party where said Third Party uses, sells, offers to sell, imports, has imported, exports, has exported and/or distributes said products.

Accelr8 explicitly grants to Nanosphere, during the Term and subject to the terms and conditions of this Agreement, the right to contract with a Third Party to manufacture the Licensed Product and apply it exclusively to Nanosphere Products, provided that Nanosphere assures compliance of said Third Party with the licensing and confidentiality terms of this Agreement.

Accelr8 shall provide to Nanosphere by 60 days after the Effective Date of the Agreement with all information necessary to produce the Licensed Product, including descriptions or specifications of machines, components and materials used for the production. Accelr8 shall also provide to Nanosphere by 75 days after the Effective Date of the Agreement with a detailed and complete documentation of Accelr8’s production processes.

The license and rights granted by Accelr8 in §2.01 are subject to the following:

(a) Nanosphere may not sublicense the license and rights granted to it hereunder to any Third Party, including, any Affiliate, except under Article 2.02;

(b) the Licensed Product must be applied to a proprietary Nanosphere Product including products produced by Nanosphere for any Third Party where said Third Party uses, sells, offers to sell, imports, has imported, exports, has exported and/or distributes said products;

(c) the Nanosphere Product that includes the Licensed Product must be appropriately labeled for use and sale with respect to applicable patent law

Accelr8 hereby reserves all rights in and to the Accelr8 Intellectual Property not expressly granted to Nanosphere hereunder, including, without limitation, the right to make, have made, use, sell, offer to sell, import and export the Accelr8 product of Appendix B.

Each of the Parties will provide to the other Party, on a time and materials basis as reasonably requested by the other Party, technical support and consulting services related to the Licensed Product subject to mutual agreement on applicable terms and conditions as represented by a written letter of agreement.

None.

License Fee. Nanosphere shall pay to Accelr8 a non-refundable fee of one-million eight-hundred and fifty dollars ($1,850,000) in four annual installments. On the Effective Date, Nanosphere shall pay to Accelr8 a non-refundable installment of one-hundred fifty thousand Dollars ($150,000). Upon the first anniversary of the Effective Date (July 9th, 2011) Nanosphere shall pay to Accelr8 a non-refundable installment of three-hundred and fifty thousand dollars ($350,000). Upon the second anniversary of the Effective Date (July 9th, 2012) Nanosphere shall pay to Accelr8 a non-refundable installment of six-hundred thousand dollars ($600,000). Upon the third anniversary of the Effective Date (July 9th, 2013) Nanosphere shall pay to Accelr8 a non-refundable installment of seven-hundred and fifty thousand dollars ($750,000). Failure to complete any installment payment in a timely manner shall result in notice of Termination by Accelr8 to Nanosphere under §10.02 and subsequent effects of Termination. If all the listed patents in APPENDIX A and patents that issue there from are declared invalid during the Term of this Agreement, Nanosphere will not be obligated to make any remaining payments.

Nanosphere shall pay to Accelr8 a one-time fee of fifteen-thousand Dollars ($15,000) for the transfer of technology of §2.02 to Nanosphere (“Technology Transfer”), payable within thirty (30) days of the Effective Date. Such Technology Transfer will be completed upon Accelr8’s statement of delivery of the documentation of §2.02.

Accelr8 agrees to provide additional consulting services for technical support at a rate of two-hundred Dollars ($200) per hour, one (1) day minimum, for the term of this Agreement, if and as requested by Nanosphere.

All payments hereunder shall be payable in U.S. Dollars. When conversion of payments from any foreign currency is required, such conversion shall be at an exchange rate equal to the rate of exchange for the currency of the country from which the fees are payable as published by The Wall Street Journal, East Coast Edition, on the final day of the Calendar Quarter for which a payment is due. In any country where conversion of the local currency is blocked and such currency cannot be removed from the country, at the

election of Accelr8 fees accrued in that country may be paid to Accelr8 in that country in local currency by deposit in a local bank designated by Accelr8. All payments other than those specified in the preceding sentence shall be payable to Accelr8 by wire transfer, in immediately available funds, to a bank account as may be designated by Accelr8 in writing from time to time.

If laws or regulations require that taxes be withheld from payments due to Accelr8 hereunder, Nanosphere shall have the right to (a) deduct such taxes from the payment due to Accelr8 hereunder, (b) timely pay the taxes to the proper taxing authority, and (c) send evidence of the obligation together with proof of tax payment (including certification of receipt by the taxing authority) to Accelr8 within thirty (30) days following such tax payment. Notwithstanding the foregoing, Nanosphere shall cooperate with Accelr8 and shall execute and deliver such documents and take such other actions as Accelr8 may reasonably request, for the purpose of (x) obtaining an exemption from the tax withholding requirements of any foreign country, (y) obtaining a refund of any taxes actually withheld by Nanosphere and paid to a foreign country pursuant to tax withholding requirements, and (z) otherwise seeking to lawfully mitigate the amount of taxes required to be withheld from any payments due to Accelr8 hereunder pursuant to applicable foreign tax law.

Any amounts not paid by Nanosphere when due under this Agreement shall be subject to interest from and including the date payment is due through and including the date upon which Accelr8 has actually received payment at a rate equal to the sum of two percent (2%) plus the prime rate of interest quoted in the Money Rates section of The Wall Street Journal, East Coast Edition, calculated daily on the basis of a 365-day year, or similar reputable data source, or, if lower, the highest rate permitted under applicable law. The payment of such interest shall not limit Accelr8 from exercising any other rights or remedies it may have as a consequence of the lateness of any payment.

Ownership of Inventions and Information. Ownership of Inventions shall be determined in accordance with the following rules:

(a) Nanosphere shall own any Inventions (including all intellectual property rights therein) that it solely makes or conceives (“Nanosphere Inventions”).

(b) Accelr8 shall own any Inventions (including all intellectual property rights therein) that it solely makes or conceives.

(c) For any Inventions (including all intellectual property rights therein) that the Parties jointly make or conceive (“Joint Inventions”), the Parties shall jointly own any Joint Inventions, subject to the restrictions in §6.01(d).

(d) For all Joint Inventions that are jointly owned by the Parties, each Party is free to utilize such Joint Invention without accounting or reporting to the other Party, except that neither Party will assign, license, sublicense, sell, distribute or otherwise transfer any such Joint Inventions to any competitor of the other Party.

Prosecution and Maintenance of Patents. Each Party shall control the preparation, filing, prosecution and maintenance (including without limitation conducting or participating in interferences or oppositions), at its own expense, of any and all Patents that it owns. The Parties shall jointly control the preparation, filing, prosecution and maintenance (including without limitation conducting or participating in interferences or oppositions), of any and all Patents that are jointly owned by the Parties (“Joint Patents”), and to equally share all outside legal fees and expenses associated therewith. However, if a Party desires not to file, prosecute, issue or maintain an application for a Joint Patent in any particular country or jurisdiction, such Party shall notify the other Party of its intention not to do so, and with such notice shall relinquish its interest in the same (i.e., shall have no further ownership interest in, license or right to use, or any costs associated therewith) in such particular country or jurisdiction, and the other Party shall have the right, but not the obligation to file, prosecute, issue or maintain in its name such application or patent embodying a Joint Patent in such particular country or jurisdiction at its own expense. Accelr8 hereby grants to Nanosphere a nonexclusive, nontransferable, royalty-free license to use, copy and modify the Accelr8 Patents for the purposes of maintaining and supporting the Accelr8 Patents. Nanosphere covenants and agrees that it will not exercise the license rights granted in this section unless and until Accelr8 materially breaches its maintenance obligations under this Agreement.

Cooperation of the Parties. At the reasonable request of the responsible Party, the other Party agrees to reasonable efforts to cooperate in the preparation, filing, prosecution, maintenance and defense of any Patents under this Agreement and in the obtaining and maintenance of any patent extensions, supplementary protection certificates and the like with respect to any Patent claiming an Invention. Such cooperation includes, but is not limited to:

(a) executing all papers and instruments (including assignment documents), or requiring its employees or contractors, to execute such papers and instruments, so as to effectuate the ownership of inventions set forth in §6.01, and Patents claiming such inventions, and to enable the responsible Party to apply for and to prosecute patent applications in any country; and

(b) promptly informing the other Party of any matters coming to the first Party’s attention that may affect the preparation, filing, prosecution or maintenance of any such patent applications.

Infringement by Third Parties. Each Party agrees to inform the other Party promptly in writing of any suspected infringement of the Accelr8 Technology, the Licensed Product and/or the Patents resulting from any Inventions. The Party owning the applicable Patent shall have the sole right to institute suit against such Third Party, provided that the other Party shall provide all reasonable cooperation and assistance that may be requested by the first Party, at the first Party’s expense, in any such suit, which cooperation may include joining in such suit.

In the performance of this Agreement, each Party may disclose directly or indirectly to the other party certain confidential information, orally or in writing or both, including, but not be limited to, marketing plans, cost or price data, customer or supplier information, technical information, patent applications, and patent prosecution documents regarding the Accelr8 Technology or the Licensed Product (collectively, “Confidential Information”). Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the disclosing Party, the Parties agree that, during the Term for at least five (5) years and thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential Information. A Party may use such Confidential Information only to the extent required to accomplish the purposes of this Agreement. Neither Party will use any Confidential Information of any other Party for any purpose or in any manner that would constitute a violation of any laws or regulations, including, without limitation, the export control laws of the United States. Neither Party may reproduce any Confidential Information of any other Party in any form except as required to accomplish the intent of this Agreement. Neither Party may disclose Confidential Information of any other Party to any employee, agent, consultant, or sublicensee who does not have a reasonable need for such information for purposes of performance under this Agreement and who is not subject to binding obligations of confidentiality and limited use at least as restrictive as those of this Article 8. In particular, neither Party will disclose to a Third Party any legal opinions with regard to Accelr8’s Intellectual Property without first obtaining a “Community of Interest” agreement from such Third Party that includes Accelr8 as named in the Community of Interest. Each Party will use at least the same standard of care as it uses to protect its own proprietary or confidential information of a similar nature to prevent unauthorized disclosures or uses of Confidential Information of the other Party, but in no event less than reasonable care. Each Party will promptly notify the disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.

The obligations of confidentiality and non-use of Confidential Information set forth in §7.01 above shall not apply to any information that, as shown by competent proof:

(a) is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party in breach hereof, generally known or available;

(b) is known by the receiving Party at the time of receiving such information;

(c) is hereafter furnished to the receiving Party by a Third Party, as a matter of right and without restriction on disclosure;

(d) is independently developed by the receiving Party without use of or reference to Confidential Information of the other Party; or

(e) is the subject of a prior, express, written permission to disclose provided by the disclosing Party.

The Parties agree that the material financial terms of this Agreement shall be considered Confidential Information of both Parties. Notwithstanding the foregoing, the Parties may disclose such terms to bona fide potential corporate partners, potential investors or merger or acquisition partners, and to financial underwriters and legal and financial advisors; provided that all such disclosures shall be made only to such parties under obligations of confidentiality and non-use and provided the other Party is informed to whom such disclosures will be made.

Each of the Parties may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary for complying with applicable court orders or governmental regulations.

Notwithstanding the foregoing, in the event that a Party is required to make a disclosure of any other Party’s Confidential Information pursuant to §7.03 it will give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such information at least as diligent as the other Party would use to protect its own confidential information, but in no event less than reasonable efforts. In any event, each of the Parties agrees to take all reasonable action to avoid disclosure of Confidential Information hereunder. The Parties will consult with each other on the provisions of this Agreement to be redacted in any filings made by the parties with the United States Securities and Exchange Commission or as otherwise required by law.

Each Party shall have the right to review and comment on any material proposed for disclosure or publication by the other Party, such as by oral presentation, manuscript or abstract, which utilizes Confidential Information of the non-publishing Party. Before any such material is submitted for publication, the Party proposing publication shall deliver a complete copy to the non-publishing Party whose Confidential Information is utilized therein, at least thirty (30) days prior to submitting the material to a publisher or initiating any other disclosure. The non-publishing Party shall review any such material and give its comments to the Party proposing publication within thirty (30) days of the delivery of such material to the non-publishing Party. With respect to oral presentation materials and abstracts, the non-publishing Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the Party proposing publication with appropriate comments, if any, but in no event later than thirty (30) days from the date of delivery to the non-publishing Party. The publishing Party shall comply with the non-publishing Party’s requests to delete references to the non-publishing Party’s Confidential Information in any such material and agrees to delay any submission for publication or other public disclosure for a period of up to an additional ninety (90) days for the purpose of preparing and filing appropriate patent applications.

The Parties shall issue a mutually acceptable press release regarding this Agreement and the Parties’ collaboration upon execution of this Agreement.

ACCELR8 IS LICENSING AND PROVIDING THE ACCELR8 TECHNOLOGY ON AN “AS IS” BASIS, AND IT MAKES NO REPRESENTATIONS NOR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE ACCELR8 TECHNOLOGY OR THE USE, SALE, IMPORT, EXPORT OR OTHER DISPOSITION BY NANOSPHERE, ITS AFFILIATES, SUBLICENSEE(S), OR THEIR VENDEES OR OTHER TRANSFEREES OF LICENSED PRODUCTS. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE, MANUFACTURE, SALE OR IMPORT OF LICENSED PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, SERVICE MARK, OR OTHER RIGHTS OF ANY THIRD PARTY.

Accelr8 and Nanosphere each hereby represent and warrant to the other as follows:

(a) it is duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority and the legal right to (i) own and operate its property and assets, (ii) carry on its business as it is now being conducted and as contemplated in this Agreement, and (iii) enter into this Agreement and to carry out the provisions hereof;

(b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action; and

(c) this Agreement is legally binding upon it and enforceable in accordance with its terms, and (ii) the execution, delivery and performance of this Agreement by it does not conflict with any written agreement, instrument or understanding to which it is a party or by which it may be bound, or violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.

Nothing in this Agreement shall be construed as:

(a) A warranty or representation by Accelr8 to the validity or scope of any of the Accelr8 Patents;

(b) A warranty or representation that the Accelr8 Technology or anything made, used, sold, imported or otherwise disposed of under the licenses granted hereunder (including, without limitation, the Licensed Product) will or will not infringe patents, copyrights or other rights of Third Parties. However Accelr8 has, as of the Effective Date, no knowledge of any such infringements and no actions have been alleged or filed against Accelr8 with respect to claims of invalidity of the Licensed Patents or infringement;

(c) An obligation to furnish any know-how or technology not agreed to in this Agreement, to bring or prosecute actions or suits against Third Parties for infringement or to provide any services other than those specified in this Agreement.

Nanosphere covenants that it shall:

(a) cause Licensed Products sold under this Agreement to be marked with the notice of the patent numbers or patent pending, as may be legally required.

(b) comply with all laws and regulations of the United States and any other country as appropriate concerning or controlling the import or export of Licensed Products.

(c) comply with all laws and regulations of the country as concerned with regard to the manufacture, marketing, promotion or distribution of Licensed Products.

(d) appropriately label Nanosphere Products for use and sale, including, without limitation, any restrictions on use in the instructions for use.

Except in connection with liability for breach of Article 8, no Party shall be entitled to recover from the other Party any special, incidental, indirect, consequential or punitive damages in connection with this Agreement or any license granted hereunder; provided, however, that this §8.05 shall not be construed to limit any Party’s indemnification obligations under Article 9 or any remedies available at law for a violation of a Party’s intellectual property or proprietary rights.

Nanosphere Indemnification. Nanosphere shall indemnify and hold Accelr8 and its Affiliates, and their respective officers, directors, employees, consultants and agents (each, an “Accelr8 Indemnitee”) harmless from and against all liability, damages, losses, costs and expenses including reasonable attorneys fees and expenses (collectively, “Losses”), in connection with a claim asserted by a Third Party for death, personal injury, illness, property damage, noncompliance with applicable laws and any other Third Party claim, proceeding, demand, (each, a “Third Party Claim”) in connection with or arising out of:

(a) any use of the Accelr8 Technology in a manner not expressly permitted under the licenses granted to Nanosphere hereunder;

(b) the design, manufacture, use, production, marketing, sale or distribution of Licensed Products except where such Third Party Claim is based solely on allegation(s) that Nanosphere’s use of the Accler8 Intellectual Property as allowed by this Agreement infringes patents, copyrights or other rights of such Third Party;

(c) any representation or warranty made by Nanosphere in Article 8 of this Agreement; or

(d) the gross negligence or willful misconduct of Nanosphere; or

(e) any claims that the manufacture, use, sale or import of the Licensed Products solely done by or through Nanosphere infringes or violates any patent or other rights of any Third Party. However, no indemnification applies by Nanosphere for Accelr8 and its Affiliates, and their respective officers, directors, employees, consultants and agents (each, an “Accelr8 Indemnitee”) for any actions arising from, but not limited to, §2.04.

Control of Defense. Accelr8 shall give prompt written notice of a Third Party Claim to Nanosphere and Nanosphere shall defend against such Third Party Claim with the reasonable cooperation of the Accelr8 Indemnitee; provided that (i) Accelr8 shall have the exclusive right to control the defense or settlement of any Third Party Claim involving the validity, enforceability or scope of any Accelr8 Intellectual Property or Patents owned by Accelr8 notwithstanding anything to the contrary herein, and (ii) subject to item (i) above, the Accelr8 Indemnitee will not settle any such Third Party Claim without the prior written consent of Nanosphere, which consent shall not be unreasonably withheld, conditioned or delayed. Each Accelr8 Indemnitee shall have the right to be present in person or through counsel at substantive legal proceedings relating to the applicable Third Party Claim.

Term. This Agreement shall become effective as of the Effective Date with a term ending on the expiration date of the last Patent issued as defined by this Agreement, unless earlier terminated pursuant to §10.02

Termination. This Agreement shall terminate if either Party gives written notice to the other Party of the other Party’s material breach of the terms of this Agreement, and the other Party fails to cure such breach within thirty (30) days of its receipt of such notice.

Effect of Termination.

(a) Upon termination of this Agreement, the licenses and rights granted to Nanosphere hereunder shall immediately terminate manufacturing of Nanosphere Products that use the Licensed Product, however, Nanosphere retains the rights to use or sell all finished goods and then current work in process

(b) Within thirty (30) days following the expiration or termination of this Agreement, each Party shall deliver to the other Party any and all copies of any documents or tangible items that contain any Confidential Information of the other Party in its possession or under its control, except that each party may keep one copy of all such Confidential Information for its legal records.

Accrued Rights and Obligations; Survival. Expiration or termination of this Agreement shall not affect any accrued rights or obligations of any Party. The provisions of Articles 5-9 and 11-12, and §§2.04, 5.02-5.06, and 10.03-10.06 of this Agreement shall survive expiration or termination of this Agreement for any reason (subject to any subsequent dates of termination referred to in such individual Articles and Sections).

Exercise of Right to Terminate. If any Party elects to terminate this Agreement pursuant to the terms of this Article 11, such Party will not be required to compensate the other Party for any damage or loss that such other Party may suffer as a result of the terminating Party exercise of its rights under this Article 10.

Damages; Relief. Subject to §10.05 above, termination of this Agreement shall not preclude either Party from claiming any other damages, compensation or relief that it may be entitled to under the terms of this Agreement or at law or equity upon such termination.

In the event of any dispute arising out of or relating to this Agreement, the affected Party shall promptly notify the other Party (“Notice Date”), and the Parties shall attempt in good faith to resolve the matter. Any disputes not so resolved shall be referred to senior executives of the Parties, who shall meet at a mutually acceptable time and location within thirty (30) days of the Notice Date and shall attempt to negotiate a settlement. If the senior executives of the Parties fail to meet within thirty (30) days of the Notice Date, or if the matter remains unresolved for a period of sixty (60) days after the Notice Date, either Party may at any time thereafter and upon notice to the other Party, submit such dispute to be finally settled by arbitration administered by the American Arbitration Association in accordance with its International Arbitration Rules, as such rules may be modified by the following provisions of this Article 11.

Not later than 30 days after commencement of the arbitration, the Parties shall select one arbitrator from the AAA’s Roster of Neutrals, provided that such arbitrator shall in any event be a patent attorney with significant experience in the biotechnology industry. If the Parties are unable to agree on an arbitrator, an arbitrator meeting the above qualifications shall be selected in accordance with AAA’s rules not later than 60 days after commencement of the arbitration. The place of the arbitration shall be Denver County, Colorado.

The arbitration shall be governed by the substantive laws of the State of Colorado without regard to conflict of law rules, Title 9 of the US Code (United States Arbitration Act) and the Commercial Arbitration Rules of the American Arbitration Association, except to the extent expressly limited by this Article 11.

Each Party shall have the right to request from the arbitrators, and the arbitrators shall order upon good cause shown, reasonable and limited prehearing discovery, including (a) exchange of witness lists, (b) depositions under oath of named witnesses at a mutually convenient location, (c) written interrogatories, and (d) document requests. Any dispute regarding discovery, or the relevance or scope thereof, shall be determined by the arbitrator, which determination shall be conclusive. All discovery shall be completed

within forty five (45) days following the appointment of the arbitrator. Upon conclusion of the pre-hearing discovery, the arbitrator shall promptly hold a hearing upon the evidence to be adduced by the Parties and shall promptly render a written opinion and award.

The arbitrator will have no authority to award any damages inconsistent with the terms of this Agreement except as may be required by statute. Judgment on the award may be entered by any court of competent jurisdiction.

Each Party shall bear its own costs and expenses in relation to such arbitration, provided, however, that the Parties shall share equally the costs and expenses of the arbitrator.

Assignment. Except as expressly provided hereunder, no Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that any Party may assign this Agreement and its rights and obligations hereunder without the other Party’s consent to an Affiliate or in connection with the transfer or sale to a Third Party of all or substantially all of the assets or outstanding capital stock of such Party, whether by merger, sale of stock, or sale of assets. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be void.

Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Colorado, excluding its choice of law principles.

Bankruptcy Code 365(n). The Parties acknowledge that the Accelr8 Intellectual Property is “intellectual property” for purposes of Section 365(n) of the U.S. Bankruptcy Code and that Licensee will have the right to exercise all rights provided by Section 365(n) with respect to the Accelr8 Intellectual Property. In the event of a filing of bankruptcy by or against either Party, such Party is required to expeditiously decide to accept or reject a license within a reasonable time and not oppose a motion by the other Party to compel assumption or rejection of the license. In the event that Accelr8 materially breaches its transfer of technology obligations to Nanosphere as set forth in §2.02 under this Agreement, Nanosphere shall have the right to require the transfer by Accelr8 (or in the event of a filing of bankruptcy by or against Accelr8, by the trustee) to Nanosphere of all information and materials in deficiency and required to complete the transfer of technology (including all embodiments thereof) as set forth in §2.02.

Notices. Any notice or other communication required or permitted to be given to any Party hereto shall be in writing unless otherwise specified and shall be deemed to have been properly given and effective: (a) on the date of delivery if delivered in person; (b) the date of electronically confirmed facsimile transmission if during the recipient’s normal business hours, or otherwise on the next business day of the recipient; (c) one (1) business day after sending via next business day delivery by a nationally recognized overnight courier service; or (d) three (3) days after mailing by registered or certified mail, postage prepaid and return receipt requested, to the Party to be notified at the following address or facsimile number:

In the case of Accelr8:

Accelr8 Technology Corporation
7000 North Broadway, Bldg 3-307
Denver, Colorado 80221
Facsimile: + ###-###-####
Attention: Thomas V. Geimer, Chairman and CEO
CC: President

In the case of Nanosphere:

Nanosphere Inc.
4088 Commercial Avenue
Northbrook, Illinois 60062
Facsimile: (847)  ###-###-####
Attention: Winton Gibbons
CC: CFO

Any Party may change its address for communications by a notice to the other Parties in accordance with this §12.04.

Use of Name. Accelr8 grants to Nanosphere the right to use Accelr8’s name and the name of the Licensed Product in the promotion of Nanosphere Products.

Entire Agreement. The terms and provisions contained in this Agreement (including any and all Appendices referred to herein) constitute the entire Agreement between the Parties and shall supersede all previous communications, representations, agreements or understandings, either oral or written, between the parties hereto with respect to the subject matter hereof, and no agreement or understanding varying or extending this Agreement will be binding upon any Party hereto, unless in writing which specifically refers to this Agreement, signed by duly authorized officers or representatives of each of the Parties, and the provisions of this Agreement not specifically amended thereby shall remain in full force and effect according to their terms.

Severability. The provisions and clauses of this Agreement are severable, and in the event that any provision or clause is determined to be invalid or unenforceable under any controlling body of the law, such provision or clause shall, if possible, be interpreted to achieve the intent of the Parties to this Agreement to the extent possible rather than voided. In any event, such invalidity or unenforceability will not in any way affect the validity or enforceability of the remaining provisions and clauses hereof.

No Agency. The Parties relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not establish a joint venture, partnership or similar business relationship among the Parties, except as expressly set forth herein. No Party is a legal representative of any other Party hereto, and no Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of any other Party for any purpose whatsoever.

Waiver. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.

Amendment. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by duly authorized representatives of the Parties to this Agreement.

Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute a single instrument.

No Third Party Rights or Obligations. No provision of this Agreement shall be deemed or construed in any way to result in the creation of any rights or obligation in any Third Party.

Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.

Cumulative Rights. The rights, powers and remedies hereunder shall be in addition to, and not in limitation of, all rights, powers and remedies provided at law or in equity, or under any other agreement between the Parties. All of such rights, powers and remedies shall be cumulative, and may be exercised successively or cumulatively.